Eliasson Erik, Wadelius Mia
professor, överläkare, klinisk farmakologi, Karolins-ka institutet; Karolins-ka universitetslaboratoriet, Stockholm.
professor, överläkare, Klinisk farmakologi, Uppsala universitet; Akademiska laboratoriet, Uppsala; båda för arbetsgruppen för farmakogenomik, Genomic Medicine Sweden.
Lakartidningen. 2021 May 11;118:20176.
Serious adverse drug reactions, drug intolerance, and lack of effect are major problems in healthcare. Pharmacogenomics is the part of precision medicine that aims to develop predictive risk markers in this respect and establish such testing in clinical practice. The nation-wide project Genomic Medicine Sweden (GMS) is undertaking large-scale sequencing to predict risk of drug toxicity and lack of efficacy in malignant diseases. The aim is to facilitate an improved, individualized treatment with increased patient safety. In addition to accurate genotyping, other technical or infrastructure-related aspects need to be considered for a successful implementation in healthcare, for example electronic accessibility and visibility of pharmacogenomic data of long-standing relevance for an individual's ongoing and future drug treatment.
严重药物不良反应、药物不耐受和疗效不佳是医疗保健中的主要问题。药物基因组学是精准医学的一部分，旨在开发这方面的预测风险标志物，并在临床实践中开展此类检测。瑞典全国性项目“瑞典基因组医学”（GMS）正在进行大规模测序，以预测恶性疾病中药物毒性和疗效不佳的风险。其目的是促进改善个体化治疗，提高患者安全性。除了准确的基因分型外，为在医疗保健中成功实施，还需要考虑其他与技术或基础设施相关的方面，例如电子可及性以及对个人当前和未来药物治疗具有长期相关性的药物基因组数据的可见性。
